enGene plans to start detalimogene BLA by end-2026 after FDA pre-BLA meeting
The company reported updated LEGEND Cohort 1 data in BCG-unresponsive high-risk NMIBC with CIS and said it agreed the efficacy-evaluable population with the FDA.
enGene Therapeutics has said it intends to begin a biologics licence application (BLA) for detalimogene voraplasmid by the end of 2026 and to complete the submission in the first half of 2027. The plan follows a pre-BLA meeting with the US Food and Drug Administration.
According to the company, it reached agreement with the agency at that meeting on the efficacy-evaluable population. Population definitions of this kind shape which patients count toward the primary efficacy analysis in a pivotal dataset.
enGene also reported updated results from pivotal Cohort 1 of the Phase 2 LEGEND trial, in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). The data cutoff was 29 October 2026.
The complete response rate at any time was 56%. The preliminary estimate of response lasting at least 12 months was 43%. Serious treatment-related adverse events occurred in 2% of patients.
The company's statement is the only source for these figures, and the summary available does not give patient numbers or confidence intervals. The proposed submission remains subject to FDA review and acceptance.
Why it matters
- Regulatory teams tracking NMIBC should note the planned rolling-style timeline: submission start by end-2026, completion in H1 2027.
- Agreement on the efficacy-evaluable population with the FDA reduces one source of uncertainty in the pivotal analysis, though it does not predict the review outcome.
- Safety reviewers can note the low rate of serious treatment-related adverse events (2%), pending the full dataset and label-relevant detail.
- Market-access teams should treat the 12-month durability figure as preliminary, since the estimate was described as such.
Company's press release (SEC filing): enGene Therapeutics Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IRulya Therapeutics reports $105.2M cash as LAM-001 Phase 2 readouts approach
Cerenome reports first CNSide revenue and completes enrolment in Phase 2 glioblastoma trial
BeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC
Valneva: 94% of adults still seroresponders five years after single IXCHIQ dose
GH Research posts $46.6M nine-month loss as GH001 depression programme nears pivotal stage
